Jane Street Group, LLC Biomarin Pharmaceutical Inc Transaction History

Jane Street Group, LLC

$88.2 Billion
Q2 2024

A detailed history of Jane Street Group, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 209,292 shares of BMRN stock, worth $14.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

209,292

Previous 289,110 27.61%

Holding current value

$14.8 Million

Previous $25.3 Million 31.76%

% of portfolio

0.02%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $5.94 Million - $7.36 Million	-79,818 Reduced 27.61%	209,292 $17.2 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $8.93 Million - $10.6 Million	106,578 Added 58.39%	289,110 $25.3 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $4.41 Million - $5.7 Million	57,878 Added 46.43%	182,532 $17.6 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $6.44 Million - $7.15 Million	-75,714 Reduced 37.79%	124,654 $11 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $11.6 Million - $13.4 Million	134,089 Added 202.31%	200,368 $17.4 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $857,921 - $1.15 Million	-9,778 Reduced 12.86%	66,279 $6.44 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $3.73 Million - $5.01 Million	46,087 Added 153.78%	76,057 $7.87 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $1.26 Million - $1.48 Million	15,313 Added 104.48%	29,970 $2.54 Million
Q2 2022 Aug 16, 2022	SELL	$71.48 - $86.85 $5.37 Million - $6.52 Million	-75,117 Reduced 83.67%	14,657 $1.22 Million
Q1 2022 May 17, 2022	BUY	$74.28 - $92.69 $4.9 Million - $6.12 Million	65,995 Added 277.53%	89,774 $6.92 Million
Q4 2021 Feb 15, 2022	SELL	$71.72 - $91.47 $1.46 Million - $1.86 Million	-20,333 Reduced 46.09%	23,779 $2.1 Million
Q3 2021 Nov 16, 2021	SELL	$74.77 - $85.47 $2.34 Million - $2.68 Million	-31,312 Reduced 41.51%	44,112 $3.41 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $1.75 Million - $1.96 Million	23,174 Added 44.35%	75,424 $6.29 Million
Q1 2021 May 18, 2021	SELL	$74.73 - $90.69 $8.44 Million - $10.2 Million	-112,986 Reduced 68.38%	52,250 $3.95 Million
Q4 2020 Feb 17, 2021	SELL	$72.61 - $90.2 $1.95 Million - $2.43 Million	-26,907 Reduced 14.0%	165,236 $14.5 Million
Q3 2020 Nov 17, 2020	BUY	$71.87 - $131.03 $12.9 Million - $23.5 Million	179,452 Added 1414.01%	192,143 $14.6 Million
Q2 2020 Aug 17, 2020	SELL	$79.55 - $124.22 $2.33 Million - $3.63 Million	-29,262 Reduced 69.75%	12,691 $1.57 Million
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $1.73 Million - $2.35 Million	24,235 Added 136.78%	41,953 $3.55 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $272,504 - $366,208	4,240 Added 31.46%	17,718 $1.5 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $664,227 - $838,759	-9,855 Reduced 42.24%	13,478 $908,000
Q2 2019 Aug 15, 2019	BUY	$80.35 - $93.9 $716,159 - $836,930	8,913 Added 61.81%	23,333 $2 Million
Q1 2019 May 16, 2019	SELL	$84.2 - $98.62 $1.88 Million - $2.2 Million	-22,278 Reduced 60.71%	14,420 $1.28 Million
Q4 2018 Feb 15, 2019	SELL	$80.14 - $106.07 $3.2 Million - $4.24 Million	-39,958 Reduced 52.13%	36,698 $3.13 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $5.97 Million - $6.72 Million	63,551 Added 484.94%	76,656 $7.43 Million
Q2 2018 Aug 15, 2018	SELL	$76.01 - $99.03 $244,220 - $318,183	-3,213 Reduced 19.69%	13,105 $1.23 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $277,048 - $330,411	3,567 Added 27.97%	16,318 $1.32 Million
Q4 2017 Feb 15, 2018	BUY	$80.76 - $95.13 $1.03 Million - $1.21 Million	12,751	12,751 $1.14 Million

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Biomarin Pharmaceutical Inc Transaction History